GeneOne Life Science, Inc. (KRX:011000)
South Korea · Delayed Price · Currency is KRW 798.00
+78.00 (10.83%)
Last updated: Apr 16, 2026, 1:18 PM KST
GeneOne Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 23,045 | 35,720 | 40,203 | 48,718 | 38,700 |
Other Revenue | - | 0 | 0 | - | -0 |
| 23,045 | 35,720 | 40,203 | 48,718 | 38,700 | |
Revenue Growth (YoY) | -35.48% | -11.15% | -17.48% | 25.89% | -6.75% |
Cost of Revenue | 38,261 | 46,687 | 48,088 | 39,541 | 30,058 |
Gross Profit | -15,217 | -10,967 | -7,885 | 9,177 | 8,642 |
Selling, General & Admin | 18,849 | 20,804 | 26,627 | 30,867 | 21,498 |
Research & Development | 1,929 | 3,556 | 7,043 | 12,147 | 11,441 |
Amortization of Goodwill & Intangibles | 283.89 | 196.54 | 287.07 | 182.57 | 156.36 |
Other Operating Expenses | 416.7 | 503.5 | 432.8 | 295.42 | 223.23 |
Operating Expenses | 28,820 | 32,072 | 40,483 | 49,376 | 36,170 |
Operating Income | -44,036 | -43,039 | -48,368 | -40,199 | -27,527 |
Interest Expense | -5,140 | -2,156 | -1,180 | -7,309 | -4,455 |
Interest & Investment Income | 186.58 | 125.18 | 518.68 | 6,216 | 1,538 |
Currency Exchange Gain (Loss) | 159.98 | -248.79 | 107.21 | 278.95 | 4,361 |
Other Non Operating Income (Expenses) | -3,151 | -3,433 | 3,569 | 2,958 | 9,638 |
EBT Excluding Unusual Items | -51,981 | -48,751 | -45,353 | -38,056 | -16,445 |
Gain (Loss) on Sale of Investments | - | -4.25 | 4.25 | - | - |
Gain (Loss) on Sale of Assets | 43.83 | 2.82 | 3.4 | 1.31 | -106.93 |
Asset Writedown | - | - | -32,309 | - | - |
Other Unusual Items | - | - | - | - | 1,018 |
Pretax Income | -51,937 | -48,753 | -77,655 | -38,054 | -15,534 |
Income Tax Expense | -86.36 | -216.19 | 113.45 | 95.79 | 353.75 |
Net Income | -51,851 | -48,537 | -77,768 | -38,150 | -15,888 |
Net Income to Common | -51,851 | -48,537 | -77,768 | -38,150 | -15,888 |
Shares Outstanding (Basic) | 82 | 79 | 78 | 77 | 74 |
Shares Outstanding (Diluted) | 82 | 79 | 78 | 77 | 74 |
Shares Change (YoY) | 3.77% | 2.17% | 0.34% | 4.37% | 22.98% |
EPS (Basic) | -629.00 | -611.00 | -1000.23 | -492.35 | -214.00 |
EPS (Diluted) | -629.00 | -611.00 | -1000.23 | -492.35 | -214.00 |
Free Cash Flow | -16,565 | -19,356 | -27,345 | -69,419 | -87,291 |
Free Cash Flow Per Share | -200.95 | -243.66 | -351.70 | -895.90 | -1175.77 |
Gross Margin | -66.03% | -30.70% | -19.61% | 18.84% | 22.33% |
Operating Margin | -191.09% | -120.49% | -120.31% | -82.51% | -71.13% |
Profit Margin | -225.00% | -135.88% | -193.44% | -78.31% | -41.05% |
Free Cash Flow Margin | -71.88% | -54.19% | -68.02% | -142.49% | -225.56% |
EBITDA | -25,840 | -25,078 | -35,592 | -34,776 | -22,877 |
EBITDA Margin | -112.13% | -70.21% | -88.53% | -71.38% | -59.11% |
D&A For EBITDA | 18,196 | 17,961 | 12,776 | 5,424 | 4,650 |
EBIT | -44,036 | -43,039 | -48,368 | -40,199 | -27,527 |
EBIT Margin | -191.09% | -120.49% | -120.31% | -82.51% | -71.13% |
Advertising Expenses | 320.19 | 381.32 | 196.96 | 341.71 | 194.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.